With many doctors around the world sharing their success stories about the effectiveness of hydroxychloroquine  for treatment of COVID-19 patients, today, the American Thoracic Society issued suggestions Monday that counsel COVID-19 people with pneumonia get doses of the anti-malaria drug.

The medical group, which was founded in 1905 to combat TB, the ATS has grown to tackle asthma, COPD, lung cancer, sepsis, acute respiratory distress, and sleep apnea, among other diseases, said evidence about the impact of hydroxychloroquine is “contradictory” but it is worth experimenting with during a public health crisis to treat very sick patients.

“We believe that in urgent situations like a pandemic, we can learn while treating by collecting real-world data,” said Dr. Kevin Wilson, chief of guidelines and documents at the American Thoracic Society.

Read full article here: https://techstartups.com/2020/04/06/american-thoracic-society-backs-the-use-of-malarial-drug-hydroxychloroquine-for-treatment-of-coronavirus-patients/

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories